WeVote
Log In

Bill

Bill

HB 572

Public Health - Opioid Overdose Reversal Drugs

2025 Regular Session Introduced by Nic Kipke

HB 572 would establish opioid overdose reversal drug protocols in Maryland but was withdrawn by sponsor on March 15, 2025, before passage.

Withdrawn by Sponsor
0
WeVote Research Nonpartisan
Bill Summary · HB 572

Legislative bill overview

HB 572 would establish public health measures related to opioid overdose reversal drugs (such as naloxone/Narcan) in Maryland. The bill's specific provisions are not detailed in the available action history, but based on the title and sponsorship, it likely addresses accessibility, distribution, or administration protocols for these life-saving medications.

Why is this important

Opioid overdose deaths remain a significant public health crisis in Maryland and nationally. Expanding access to overdose reversal drugs has been shown to reduce fatal overdoses and is a cornerstone of harm reduction strategies supported by public health organizations.

Potential points of contention

  • Scope of access: Disagreement over who should be able to distribute or administer naloxone (pharmacists, harm reduction programs, first responders, bystanders)
  • Funding mechanisms: Questions about whether the state or healthcare providers should bear costs for purchasing and distributing the medication
  • Implementation details: Concerns about training requirements, liability protections, or insurance coverage frameworks that the bill may or may not have addressed

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.